打开APP

PaxVax霍乱疫苗临床三期研究获得成功

  1. PaxVax
  2. 霍乱疫苗

来源:生物谷 2014-07-06 19:27

PaxVax霍乱疫苗临床三期研究获得成功

2014年7月6日讯 /生物谷BIOON/ --著名疫苗研究公司PaxVax公司最近宣布,公司开发的新型霍乱疫苗PXVX0200临床三期研究圆满结束,研究取得非常理想的结果。根据PaxVax公司披露的数据,在患者接受PXVX0200免疫后90天,对霍乱的抵抗率达到79.5%,而免疫10天后的有效率则高达90.3%。在整个研究中都采用双盲实验,研究人员与患者均不知道接种的是安慰剂或是疫苗。PXVX0200的另一个特点是接种者只需要接受一次免疫即可达到预防效果,远远优于以往的产品。这也十分适用于旅行者以及发展中国家的患者使用。

霍乱疾病是一种严重的传染病,每年大约有10万到13万人死于这一疾病。(生物谷Bioon.com)

详细英文报道:

New Efficacy Data Adds to Successful Phase 3 Clinical Trial Program Results for Single-Dose Oral Cholera Vaccine for Travelers' Market and People in the Developing World

REDWOOD CITY, Calif., Jul 01, 2014 (BUSINESS WIRE) -- PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced positive efficacy results from the 90-day challenge studies of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103-HgR) previously approved and marketed in several countries under the brand name Orochol. Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo.

Vaccine efficacy was evaluated by immunizing volunteer participants with an oral dose of the PXVX0200 vaccine or placebo and then subsequently exposing them to the cholera-causing agent (Vibrio cholerae O1 El Tor). Volunteer participants in this challenge study were divided into two groups - the first group was vaccinated and then challenged at 10 days after vaccination, and a second, separate group of volunteer participants was challenged at 90 days post vaccination to further evaluate duration of vaccine protection.

In an analysis of participants challenged at 90 days post vaccination with wild type, fully pathogenic cholera bacteria, the efficacy rate was 79.5 percent - four of 33 participants who received PXVX0200 experienced moderate-to-severe diarrhea compared to 39 of 66 participants who received placebo. In the 10-day study group, post vaccination with wild type, fully pathogenic cholera bacteria, the efficacy rate was 90.3 percent - two of 35 participants who received PXVX0200 experienced moderate-to-severe diarrhea compared to 39 of 66 participants who received placebo.

Study Investigator Beth Kirkpatrick, M.D., Professor of Medicine, Infectious Disease Medicine, Department of Medicine, University of Vermont commented: "The 90-day challenge results are very encouraging and provide important new data that further support the efficacy of PXVX0200 in protecting people exposed to cholera. If approved, PXVX0200 has the potential to provide an effective new single-dose option for people living in and travelling to areas where cholera is endemic."

In addition to the 10- and 90-day cholera challenge studies, immunogenicity, safety, and lot-to-lot consistency of the PXVX0200 cholera vaccine are being evaluated in a broader population at study sites in Australia, Canada, and the U.S. Approximately 3,000 participants are being enrolled in these additional pivotal Phase 3 clinical studies.

"These favorable data build on a successful 10-day challenge study and provide important new data to support a Biologics License Application for PXVX0200, our lead commercial vaccine candidate," said Kenneth Kelley, Chief Executive Officer of PaxVax. "U.S. travelers currently have limited options to protect themselves from cholera, and we are pleased with the progress we are making in bringing an effective and logistically simple, single-dose cholera vaccine to travelers as well as developing countries for use during fast-moving cholera outbreaks."

Cholera is an acute intestinal diarrheal infection caused by toxigenic Vibrio cholerae bacteria generally acquired by ingesting contaminated water or food. According to the World Health Organization, the global disease burden is estimated to be three to five million cases and 100,000 to 130,000 deaths per year. Cholera often manifests as explosive epidemics that rapidly move through populations, such as the outbreaks that occurred in Peru and Haiti in 1991 and 2010, respectively.

A vaccine for cholera is not currently available for U.S. residents who travel abroad to areas where cholera poses a risk, such as Haiti or Central Africa. A cholera vaccine is available in Europe and elsewhere for travelers, but it requires a two-dose regimen. If licensed, the single-dose, oral PXVX0200 vaccine would be more convenient for all travelers, particularly for those traveling on short notice.

The 10- and 90-day challenge efficacy studies were randomized, double-blind, and placebo-controlled trials conducted at three top vaccine testing centers: the Center for Vaccine Development of the University of Maryland School of Medicine, the University of Vermont Vaccine Testing Center, and Cincinnati Children's Hospital Medical Center.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->